Role of cytokines in the response to erythropoietin in hemodialysis patients

被引:118
作者
Goicoechea, M
Martin, J
De Sequera, P
Quiroga, JA
Ortiz, A
Carreño, V
Caramelo, C
机构
[1] Univ Autonoma Madrid, Fdn Jimenez Diaz, Lab Nefrol, Madrid 28040, Spain
[2] Univ Autonoma Madrid, Fdn Renal Inigo Alvarez Toledo, Serv Nefrol, Madrid 28040, Spain
[3] Univ Autonoma Madrid, Fdn Renal Inigo Alvarez Toledo, Lab Hepatol, Madrid 28040, Spain
关键词
cytokines; hemodialysis; erythropoietin responsiveness; interleukins; tumor necrosis factor-alpha; interferon-gamma;
D O I
10.1046/j.1523-1755.1998.00084.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Cytokines are regulatory factors of erythropoiesis, especially in pathologic conditions. Even though a relevant role for a deranged cytokine production in the pathogenesis of dialysis anemia has been suggested, no data are available that analyze the role of cytokines in the key therapeutic issue of the needs of erythropoietin. The aim of the present study in hemodialysis patients was, therefore, to examine the relationship between the dose of recombinant human erythropoietin (EPO) and the production of cytokines by peripheral blood mononuclear cells (PBMC). Methods. After the exclusion of subjects with major active causes of EPO resistance, data from 34 hemodialysis patients were available for analysis. Cytokine levels were measured in the supernatants of stimulated [with bacterial lipopolysaccharide and interferon gamma (IFN-gamma)] and unstimulated PBMC. Mean yearly values of hematocrit, hemoglobin, transferrin saturation, ferritin, parathormone (PTH) and aluminum levels and EPO doses (U/kg/wek) were calculated. For analysis, the 34 patients were divided according to their cutoff requirements for EPO: patients with requirements of EPO greater than or equal to 60 U/kg/week (group A(1), 26 subjects) versus EPO < 60 U/kg/week (group B-1, 8 subjects) and patients with requirements of EPO greater than or equal to 100 U/kg/week (group A(2) 18 subjects) versus <100 U/kg/week (group B-2, 16 subjects). Results. A significant direct correlation between interleukin-6 (IL-G) and tumor necrosis factor alpha (TNF-alpha) production values and EPO doses was found (P = 0.039 and P = 0.02 respectively). On the other hand, there was a significantly negative correlation between interleukin-l? (IL-12) production values and EPO doses (P = 0.029). Patients of groups A(1) and A(2) had spontaneously higher tumor necrosis factor-alpha (TNF-alpha) and lower IL-12 and IFN gamma production compared to patients from groups B-1 and B-2. Conclusions. Our data disclose a previously undescribed pattern of cytokine alteration that is relevant to determine increased needs of EPO in hemodialysis patients. The present results have potential applicability in designing strategies to improve EPO resistance.
引用
收藏
页码:1337 / 1343
页数:7
相关论文
共 35 条
[1]   THE CYTOKINE NETWORK [J].
BALKWILL, FR ;
BURKE, F .
IMMUNOLOGY TODAY, 1989, 10 (09) :299-303
[2]   High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients [J].
Barany, P ;
Divino, JC ;
Bergstrom, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (04) :565-568
[3]  
BELLONE G, 1994, J IMMUNOL, V153, P930
[4]  
BROXMEYER HE, 1983, J IMMUNOL, V131, P1300
[5]   ROLE OF IRON-METABOLISM IN ABSORPTION AND CELLULAR UPTAKE OF ALUMINUM [J].
CANNATA, JB ;
FERNANDEZSOTO, I ;
FERNANDEZMENENDEZ, MJ ;
FERNANDEZMARTIN, JL ;
MCGREGOR, SJ ;
BROCK, JH ;
HALLS, D .
KIDNEY INTERNATIONAL, 1991, 39 (04) :799-803
[6]  
CARAMELO C, 1995, KIDNEY INT, V54, P164
[7]   INDUCTION OF INTERFERON-GAMMA PRODUCTION BY NATURAL-KILLER-CELL STIMULATORY FACTOR - CHARACTERIZATION OF THE RESPONDER CELLS AND SYNERGY WITH OTHER INDUCERS [J].
CHAN, SH ;
PERUSSIA, B ;
GUPTA, JW ;
KOBAYASHI, M ;
POSPISIL, M ;
YOUNG, HW ;
WOLF, SF ;
YOUNG, D ;
CLARK, SC ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (04) :869-879
[8]   RHUEPO HYPORESPONSIVENESS - WHO AND WHY [J].
DANIELSON, B .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 :69-73
[9]  
DESCAMPSLATSCHA B, 1993, KIDNEY INT, V43, pS135
[10]  
DESCAMPSLATSCHA B, 1995, J IMMUNOL, V154, P882